Treatment of Nongonococcal bacterial septic arthritis.
Septic arthritis carries significant morbidity and mortality, necessitating prompt, appropriate therapy with joint fluid aspiration, intravenous antibiotics, and occasionally, surgical intervention. The initial choice of antimicrobial agent is guided by the results of synovial fluid gram stain, by identification of the pathogenesis of the primary focus, or by epidemiologic factors. Adequacy of therapy is assessed by serial synovial fluid white blood cell counts and by determining antimicrobial concentrations in the joint space. The goal of treatment is a clinically normal and sterile joint. Factors that may affect antimicrobial joint penetration include the degree of joint tissue inflammation, the degree of drug protein binding, and the chemical characteristics of the drug. Perhaps most important in determining the extent of joint penetration are factors that may affect serum antibiotic concentrations, for example, dose, route of administration, volume of distribution, but rate of elimination.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use; D001170:Arthritis, Infectious / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D001239:Inhalation; D013582:Synovial Fluid; D013583:Synovial Membrane / Q000378:metabolism
D000900:Anti-Bacterial Agents